Ajay Kallam, MD
Nephrology · Dallas, TXNPI 1306003124
Payments from drug & device makers
Across 266 payments — averaging $683.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$175K
- AstraZeneca$1K
- Amgen$1K
- Vifor Pharma, Inc.$455
- Otsuka America Pharmaceutical, Inc.$419
- Bayer$385
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,79499%
- Education$911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 4 | $174,793 |
| AstraZeneca(2 entities) | 44 | $1,397 |
| Amgen(2 entities) | 44 | $1,111 |
| Vifor Pharma, Inc. | 20 | $455 |
| Otsuka America Pharmaceutical, Inc. | 15 | $419 |
| Bayer | 18 | $385 |
| GSK | 8 | $360 |
| OPKO Pharmaceuticals, LLC | 26 | $354 |
| Baxter Healthcare | 2 | $338 |
| Aurinia Pharma U.S., Inc. | 6 | $311 |
| Mallinckrodt Hospital Products Inc. | 7 | $261 |
| Akebia Therapeutics Inc | 15 | $246 |
| Boehringer Ingelheim | 10 | $234 |
| Calliditas Therapeutics US Inc. | 6 | $227 |
| Fresenius USA Marketing, Inc. | 8 | $150 |
| Lilly USA, LLC | 6 | $115 |
| Mallinckrodt Enterprises LLC | 3 | $75 |
| Novo Nordisk | 3 | $66 |
| Travere Therapeutics, Inc. | 3 | $48 |
| Ardelyx, Inc. | 2 | $42 |
| Cormedix Inc. | 1 | $30 |
| Pfizer | 2 | $28 |
| Genentech USA, Inc. | 1 | $26 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Shield Therapeutics Inc | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Renalytix AI, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Scpharmaceuticals Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
| Avenu Medical Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$181,678 in reported general payments places this provider in the 90th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 405 | $355,748 |
| JardianceEmpagliflozin | 393 | $343,337 |
| KerendiaFinerenone | 120 | $115,759 |
| VelphoroSucroferric Oxyhydroxide | 21 | $44,722 |
| LokelmaSodium Zirconium Cyclosilicate | 48 | $31,545 |
| VeltassaPatiromer Calcium Sorbitex | 21 | $31,273 |
| AuryxiaFerric Citrate | 17 | $27,538 |
| MounjaroTirzepatide | 21 | $23,516 |
| EntrestoSacubitril/Valsartan | 15 | $14,912 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $7,165 |
| Nifedipine ErNifedipine | 101 | $3,200 |
| Sevelamer Carbonate | 13 | $2,530 |
| Losartan Potassium | 173 | $1,634 |
| Amlodipine Besylate | 210 | $1,144 |
| Tamsulosin Hcl | 106 | $1,061 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,397 | $387,294453 claims |
| Boehringer IngelheimJardiance | $234 | $343,337393 claims |
| BayerKerendia | $385 | $115,759120 claims |
| Fresenius USA Marketing, Inc.Velphoro | $150 | $44,72221 claims |
| Akebia Therapeutics IncAuryxia | $246 | $27,53817 claims |
| Lilly USA, LLCMounjaro | $115 | $23,51621 claims |
| NovartisEntresto | $19 | $14,91215 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $23 | $83323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Dallas
- Ankit MehtaDallas$3M
- Irfan AghaDallas$3M
- David WojciechowskiDallas$1.6M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Mark LermanDallas$564K
- Sumit KumarDallas$561K
- Robert TotoDallas$442K
- Akinwande AkinfolarinDallas$423K
- Deepa AmberkerDallas$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.